253 related articles for article (PubMed ID: 15050896)
1. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.
Kostenuik PJ; Bolon B; Morony S; Daris M; Geng Z; Carter C; Sheng J
Bone; 2004 Apr; 34(4):656-64. PubMed ID: 15050896
[TBL] [Abstract][Full Text] [Related]
2. Biglycan deficiency interferes with ovariectomy-induced bone loss.
Nielsen KL; Allen MR; Bloomfield SA; Andersen TL; Chen XD; Poulsen HS; Young MF; Heegaard AM
J Bone Miner Res; 2003 Dec; 18(12):2152-8. PubMed ID: 14672350
[TBL] [Abstract][Full Text] [Related]
3. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model.
Yang SY; Mayton L; Wu B; Goater JJ; Schwarz EM; Wooley PH
Arthritis Rheum; 2002 Sep; 46(9):2514-23. PubMed ID: 12355500
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats.
Valenta A; Roschger P; Fratzl-Zelman N; Kostenuik PJ; Dunstan CR; Fratzl P; Klaushofer K
Bone; 2005 Jul; 37(1):87-95. PubMed ID: 15869920
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis.
Bolon B; Carter C; Daris M; Morony S; Capparelli C; Hsieh A; Mao M; Kostenuik P; Dunstan CR; Lacey DL; Sheng JZ
Mol Ther; 2001 Feb; 3(2):197-205. PubMed ID: 11237676
[TBL] [Abstract][Full Text] [Related]
6. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin mitigates tail suspension-induced osteopenia.
Bateman TA; Dunstan CR; Ferguson VL; Lacey DL; Ayers RA; Simske SJ
Bone; 2000 May; 26(5):443-9. PubMed ID: 10773583
[TBL] [Abstract][Full Text] [Related]
8. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.
Capparelli C; Morony S; Warmington K; Adamu S; Lacey D; Dunstan CR; Stouch B; Martin S; Kostenuik PJ
J Bone Miner Res; 2003 May; 18(5):852-8. PubMed ID: 12733724
[TBL] [Abstract][Full Text] [Related]
9. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.
Ominsky MS; Li X; Asuncion FJ; Barrero M; Warmington KS; Dwyer D; Stolina M; Geng Z; Grisanti M; Tan HL; Corbin T; McCabe J; Simonet WS; Ke HZ; Kostenuik PJ
J Bone Miner Res; 2008 May; 23(5):672-82. PubMed ID: 18433301
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
[TBL] [Abstract][Full Text] [Related]
11. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
[TBL] [Abstract][Full Text] [Related]
12. Retrovirus-mediated gene transfer of receptor activator of nuclear factor-kappaB-Fc prevents bone loss in ovariectomized mice.
Kim D; Cho SW; Her SJ; Yang JY; Kim SW; Kim SY; Shin CS
Stem Cells; 2006 Jul; 24(7):1798-805. PubMed ID: 16556708
[TBL] [Abstract][Full Text] [Related]
13. CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin.
Byrne FR; Morony S; Warmington K; Geng Z; Brown HL; Flores SA; Fiorino M; Yin SL; Hill D; Porkess V; Duryea D; Pretorius JK; Adamu S; Manoukian R; Danilenko DM; Sarosi I; Lacey DL; Kostenuik PJ; Senaldi G
Gut; 2005 Jan; 54(1):78-86. PubMed ID: 15591508
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F
J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
[TBL] [Abstract][Full Text] [Related]
16. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption.
Onyia JE; Galvin RJ; Ma YL; Halladay DL; Miles RR; Yang X; Fuson T; Cain RL; Zeng QQ; Chandrasekhar S; Emkey R; Xu Y; Thirunavukkarasu K; Bryant HU; Martin TJ
J Pharmacol Exp Ther; 2004 Apr; 309(1):369-79. PubMed ID: 14718597
[TBL] [Abstract][Full Text] [Related]
17. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
[TBL] [Abstract][Full Text] [Related]
18. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease.
Magal I; Lebel E; Altarescu G; Itzchaki M; Rudensky B; Foldes AJ; Zimran A; Elstein D
Br J Haematol; 2006 Apr; 133(1):93-7. PubMed ID: 16512834
[TBL] [Abstract][Full Text] [Related]
20. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
